WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/11147/7150
Browse
6 results
Search Results
Now showing 1 - 6 of 6
Article Chemosensitizing Effect of Apigenin on T-ALL Cell Therapy(Frontiers Media SA, 2025) Huseynova, N.; Baran, Z.; Khalilov, R.; Mammadova, A.; Baran, Y.T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with limited therapeutic options and frequent treatment-associated toxicities. L-asparaginase, a cornerstone in T-ALL therapy, is often restricted by hypersensitivity reactions and systemic side effects, highlighting the need for safer strategies to enhance its efficacy. This study investigated the potential of apigenin, a naturally occurring flavonoid with antioxidant and pro-apoptotic properties, to act as a chemosensitizer for L-asparaginase in MOLT-4 T-ALL cells. Cytotoxicity was assessed using the MTT assay, apoptosis by Annexin V/PI staining, cell cycle distribution by flow cytometry, and mitochondrial membrane potential by JC-1 staining. Both apigenin and L-asparaginase produced dose- and time-dependent cytotoxicity, with combination treatment resulting in reduced IC<inf>50</inf> values. Apoptotic analysis showed significantly higher apoptosis in the combination-treated groups than in single-agent groups. Cell cycle analysis revealed that apigenin induced S-phase arrest and L-asparaginase induced G1-phase arrest, while the combination disrupted cell cycle progression at multiple checkpoints. JC-1 assay further demonstrated enhanced mitochondrial depolarization, with up to a 29.2-fold increase in cytoplasmic-to-mitochondrial fluorescence ratio in combination therapy compared to L-asparaginase alone. These findings indicate that apigenin potentiates L-asparaginase-induced cytotoxicity through mitochondrial dysfunction and intrinsic apoptotic signaling. The combined use of apigenin and L-asparaginase may provide a novel strategy to improve therapeutic efficacy in T-ALL while potentially reducing the toxicity associated with high-dose L-asparaginase monotherapy. © © 2025 Huseynova, Baran, Khalilov, Mammadova and Baran.Conference Object Apoptotic Effects of Non-Edible Parts of Punica Granatum on Human Multiple Myeloma Cells(Pergamon-Elsevier Science Ltd, 2014) Kiraz, Y.; Neergheen-Bhujun, V.; Baran, Y.Conference Object Suppression of STAT5A Increases Chemotherapeutic Sensitivity in Imatinib-Resistant and Imatinib-Sensitive K562 Cells(Ferrata Storti Foundation, 2010) Baran, Y.; Baran, Yusuf; Kosova, B.; Ekiz, Hüseyin Atakan; Tezcanli, B.; Ekiz, H.; Cakir, Z.; Selvi, S.Conference Object Changes in Protein Profiles of Multiple Myeloma Cells in Response To Bortezomib(Ferrata Storti Foundation, 2012) Baran, Y.; Turan, T.; Sanli-Mohamed, G.Conference Object Therapeutic Potential of Targeting Sphingolipid Signaling Pathways in Various Types of Cancers(Pergamon-elsevier Science Ltd, 2010) Baran, Y.; Bassoy, E. Y.; Cakir, Z.; Camgoz, A.; Gencer, E. B.; Kartal, M.; Gucluler, G.Conference Object Changes in Expression Profiles of Apoptosis, Invasion, Metastasis, Angiogenesis, Transcription Factors, Cell Cycle Control and Tumour Supressor Genes in Nilotinib Treated Chronic Myeloid Leukemia Cells(Pergamon-elsevier Science Ltd, 2010) Baran, Y.; Camgoz, A.; Can, G.